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Local administration of immune activating antibodies
may increase the efficacy and reduce the immune-
related adverse events associated with systemic immu-
notherapy of cancer. Here we report the development of
a fully human agonistic CD40 antibody (IgG1), ADC-
1013, which has been optimized for local immunother-
apy by increasing potency and tumor retention. ADC-
1013 activates CD40 receptors on antigen-presenting
cells such as dendritic cells, resulting in up-regulation of
the co-stimulatory molecules CD80 and CD86, and
induction of IL-12. In addition, ADC-1013 induces
direct tumor killing of CD40+ tumors, e.g. via antibody-
dependent cellular cytotoxicity (ADCC). The anti-tumor
effects of ADC-1013 were first assessed in a bladder
cancer model (EJ) in immunodeficient NSG mice. Signif-
icant anti-tumor responses were demonstrated, and
further augmented in mice repopulated with human
moDCs/T cells. To study the anti-tumor effects related
to the immune activating properties of ADC-1013 in
more detail, a human CD40 positive transgenic mouse
(hCD40tg) in C57/BL-6 background was used. This
transgenic mouse strain has an intact immune system
and fully functional dendritic cells that are activated
upon ADC-1013 treatment. Furthermore, the dendritic
cells obtained from this strain are able to induce antigen
specific T cell activation in vitro upon stimulation with
ADC-1013. Importantly, treatment with ADC-1013 in a
syngeneic bladder cancer (MB49) model, which is
hCD40 negative, demonstrated that ADC-1013 induce
significant tumor protection and long term immunity
independent of direct tumor targeting. In addition, the
anti-tumor immunity was shown to be T-cell dependent.
To our knowledge, ADC-1013 represents the first
immunomodulatory antibody optimized for local immu-
notherapy of cancer. It is currently in late pre-clinical
development and will enter clinical trials in 2014.
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